Insights on Patient-Focused Drug Development (PFDD) OUR INSIGHTS LEARN MORE Contact Us We share our insights to keep you updated on patient engagement initiatives, trends, and regulatory guidelines Down arrow icon

OUR INSIGHTS

ISO 9001 certification
Laura Lassen
Posted by Laura Lassen
February 26, 2021

Clinigma® is now ISO 9001 certified

At Clinigma®, we are proud to announce that we have achieved an ISO 9001 certification in designing, conducting, analysing and reporting patient interviews...

Read More
The hassle of interviewing patients in clinical trials without standardised procedures
Laura Lassen
Posted by Laura Lassen
February 15, 2021

The hassle of interviewing patients in clinical trials without standardised procedures

Ensuring that internal procedures are well in place is important for any company as it helps assuring the quality of its products and/or services. In terms of this, pharmaceutical companies...

Read More
Improving the retention of patients in clinical trials
Laura Lassen
Posted by Laura Lassen
January 29, 2021

Improving the retention of patients in clinical trials

Insufficient patient retention in clinical trials is a common issue in the pharmaceutical industry. It has a number of consequences for the drug development...

Read More
Online trial investigator result meetings - what about the investigators’ feedback?
Laura Lassen
Posted by Laura Lassen
January 22, 2021

Online trial investigator result meetings - what about the investigators’ feedback?

Following the outbreak of the COVID-19 pandemic, we now see that investigator result meetings have changed their format to online interaction...

Read More
Challenges in obtaining strong feedback from a clinical trial
Jens Harald Kongsø
Posted by Jens Harald Kongsø
January 14, 2021

Five challenges in obtaining strong feedback from clinical trials and ways to overcome them

When pharmaceutical companies have completed a clinical trial, they may want to organise a result meeting with the attendance of participating...

Read More
Generating early insights on investigational drug
Jens Harald Kongsø
Posted by Jens Harald Kongsø
January 7, 2021

The value of generating early insights on your investigational drug

When pharmaceutical companies develop new medicines, they are required to comply with regulatory requirements by reporting and publishing their clinical results. Adhering to these...

Read More